- Home
- Automated
- NDF A-Z listing
- Polatuzumab Vedotin [Polivy]
P
Polatuzumab Vedotin [Polivy]
Subsidy Information and Financing Scheme
MAF
MSHL
Drug Guidance
Yes
Post-marketing information
No
Summary of Biologics
No
Active ingredient: Polatuzumab Vedotin
General information
Subsidy Information and Financing Scheme
[MAF] Polatuzumab vedotin (Polivy) Infusion 30 mg, 140 mg
Polatuzumab in combination with rituximab biosimilar (subsidised brand), cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma (DLBCL) in patients with an international prognostic index (IPI) score of 3 to 5.
[MSHL] Polatuzumab vedotin Powder For Concentrate For Solution For Infusion 30 mg, 140 mg
Polatuzumab in combination with rituximab biosimilar (subsidised brand), cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma (DLBCL) in patients with an international prognostic index (IPI) score of 3 to 5.
Polatuzumab in combination with rituximab (non-subsidised brand), cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma (DLBCL) in patients with an international prognostic index (IPI) score of 3 to 5.
Polatuzumab in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma (DLBCL).
Legend
This section shows the following:
Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs
Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List
Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List
As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.
Legend list
Indicator | Legend |
|---|---|
SDL | Standard Drug List |
MAF | Medical Assistance Fund |
SVL | Subsidised Vaccine List |
MSHL | Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List |
Drug Guidance for Subsidy
02/01/2024 Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma
The Ministry of Health’s Drug Advisory Committee has recommended:
Polatuzumab vedotin 30 mg and 140 mg powder for concentrate for solution for infusion, in combination with rituximab biosimilar (subsidised brand), cyclophosphamide, doxorubicin and prednisone, for previously untreated diffuse large B-cell lymphoma (DLBCL) with an international prognostic index (IPI) score of 3 to 5.
Funding status
[R] Polatuzumab vedotin 30 mg and 140 mg powder for concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF), for the abovementioned indication from 1 March 2024.
[NR] MAF assistance does not apply to previously untreated diffuse large B-cell lymphoma in patients with an IPI score below 3.
Clinical indications, subsidy class and MediShield Life claim limits for polatuzumab vedotin are provided in the Annex.
12/07/2022 Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended listing polatuzumab vedotin on the Medication Assistance Fund (MAF) for treating patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for haematopoietic cell transplant due to low clinical need, uncertain clinical effectiveness and unfavourable cost-effectiveness at the price proposed by the manufacturer.
Clinical indication, subsidy class and MediShield Life claim limit for polatuzumab vedotin are provided in the Annex.
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Drug availability
Formulation | Public Healthcare Institution |
|---|---|
Polivy Infusion 140 mg |
|
Polivy Infusion 30 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |